inhibiting BTK autophosphorylation and activating downstream signalling components such as phospholipase Cγ and extracellular signal-regulated kinase in response to BCR stimulation. In a mouse ...

Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of transcription (STAT)6 inhibitor KP-723 could... BioWorld Premium Enjoy extended ...

after the FDA placed it on partial clinical hold while a safety signal is investigated. The regulator is requiring Sanofi to stop dosing some patients in phase 3 trials of the BTK inhibitor ...

Median progression-free survival (PFS) reached 14 months with pirtobrutinib, an oral non-covalent BTK inhibitor, as compared with 8.7 months with investigator's choice of idelalisib (Zydelig ...